<SEC-DOCUMENT>0000950170-22-014263.txt : 20220803
<SEC-HEADER>0000950170-22-014263.hdr.sgml : 20220803
<ACCEPTANCE-DATETIME>20220803161637
ACCESSION NUMBER:		0000950170-22-014263
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220803
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220803
DATE AS OF CHANGE:		20220803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		221132833

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rcus-20220803.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-08-03T16:13:12.4192+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:rcus="http://arcusbio.com/20220803">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4bf4238c-f038-47b6-ba94-d5e703e07bb5" name="dei:AmendmentFlag" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd">false</ix:nonNumeric><ix:nonNumeric id="F_61b2860c-73c8-45b6-92d3-697c4fa9fb07" name="dei:EntityCentralIndexKey" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd">0001724521</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rcus-20220803.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_d6315451-4815-46e3-900e-dd17359d1acd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-03</xbrli:startDate><xbrli:endDate>2022-08-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8fa1abe-e71b-4da8-a560-493133adfda7" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4e66e4b-568e-4472-b647-434afa82800e" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">August 03, 2022</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9106a3a-17b0-450f-ae35-98c33f906cb6" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;min-width:fit-content;">Arcus Biosciences, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.571%;"></td>
    <td style="width:2.94%;"></td>
    <td style="width:19.571%;"></td>
    <td style="width:17.744%;"></td>
    <td style="width:40.173%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77f6fdde-1a7c-4a40-bb95-8f769f12e71d" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2144b5eb-9a91-4602-9521-3d3076cc33b9" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">001-38419</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f9a192b-52dd-478c-9173-e29a97d8699e" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">47-3898435</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e663137-3172-4170-95fe-39e68276e817" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3928 Point Eden Way</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e3ce3c9-99a1-44ad-92e0-afe13d76c1dc" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Hayward</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d99bce71-8e50-4b5c-b5c4-3d60094733d6" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40160431-678d-4ffe-aff9-d247a2a21c15" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">94545</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47756395-8107-4e55-babc-78774be22302" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(510)</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04a6de1a-bd49-46d4-834f-4a56b4f14709" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">694-6200</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47f69b45-d621-49c0-b672-c608b604c32c" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d50c704b-b9f9-4eff-ac87-e55dd397abfa" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a13a321c-0288-4dc0-bcef-7ea02074235c" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a116d8d-c101-4265-aeaa-e0ee3ba3bd1e" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69e04cd3-96c5-46cf-a875-0080f379398e" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, Par Value $0.0001 Per Share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fa77cd2-3524-4bfa-b877-288b8548f0fe" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">RCUS</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_843034bb-2173-4263-9855-2f1020726d24" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The New York Stock Exchange</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_dfea854f-8583-4302-834d-98eb653defad" contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On August 3, 2022, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2022. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.62%;"></td>
    <td style="width:2.523%;"></td>
    <td style="width:87.857%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:12.4pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="rcus-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Press release dated August 3, 2022.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:12.4pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.405%;"></td>
    <td style="width:1.159%;"></td>
    <td style="width:3.58%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:37.854%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ARCUS BIOSCIENCES, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date: August 3, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Terry Rosen, Ph. D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Terry Rosen, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Executive Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rcus-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img230044022_0.jpg" alt="img230044022_0.jpg" style="width:149px;height:52px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by year-end; Arcus and Gilead Sciences continue to expand their late-stage clinical program for domvanalimab with the goal of establishing a best-in-class anti-TIGIT antibody regimen in multiple cancers.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">An interim analysis was conducted for the ongoing Phase 1/1b ARC-8 trial of quemliclustat plus chemotherapy, with or without zimberelimab, in pancreatic ductal adenocarcinoma (PDAC); based on the results, Arcus and Gilead plan to wait for mature progression-free survival (PFS) and overall survival (OS) data, expected in 2023, to inform next steps for the PDAC program.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">On track to initiate ARC-20, a Phase 1/1b study to evaluate AB521, Arcus&#x2019;s HIF-2a inhibitor, in cancer patients in Q3 2022; data from the ongoing healthy volunteer study enable Arcus to start dose escalation in patients at a pharmacologically relevant dose level. </font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">Arcus nominated a new development candidate, AB801 (an AXL inhibitor), in the second quarter; and at least two new molecules are expected to advance into the clinic in 2023.</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">Arcus is well positioned to advance its expanding programs and portfolio, with $1.3 billion in cash and cash equivalents and funding into 2026.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">HAYWARD, Calif. &#x2013; (BUSINESS WIRE) &#x2013; August 3, 2022 &#x2013;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline update on its six clinical-stage molecules &#x2013; targeting TIGIT, the adenosine axis (CD73 and A2a/A2b), HIF-2a and PD-1 &#x2013; across multiple common cancers. Arcus and Gilead continue to rapidly advance Arcus&#x2019;s broad and diverse pipeline, and the companies remain on track to have four ongoing registrational Phase 3 trials of domvanalimab-based combinations in non-small cell lung cancer (NSCLC) and gastrointestinal (GI) cancers by year-end. Topline disclosure from the Phase 2 ARC-7 study is expected in the second half of 2022 with a planned presentation of the data at a medical conference in 2023. Arcus continues to advance its next wave of novel molecules, with at least two INDs expected in 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#x201c;This is a transformational year in the evolution of Arcus, as we expand the scope of our global clinical programs to include four registrational Phase 3 trials with domvanalimab-based combinations,&#x201d; said Terry Rosen, Ph.D., chief executive officer of Arcus. &#x201c;The data we have generated in our Phase 2 ARC-7 study support our conviction in the initiation of two new registrational Phase 3 trials with our domvanalimab plus zimberelimab anti-TIGIT / anti-PD-1 doublet regimen, and we intend to be the leader in bringing anti-TIGIT-based therapies to patients. Our strong cash position and strategic collaborations enable us to maintain competitive positioning and execute efficiently in disease areas with significant patient populations and high unmet need, including lung and upper GI cancers.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Anti-TIGIT program (domvanalimab and AB308)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Update on Domvanalimab:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus is on track to complete enrollment in Q3 2022 of 150 patients for ARC-7, a randomized Phase 2 study evaluating the safety and efficacy of zimberelimab alone vs. domvanalimab plus zimberelimab vs. domvanalimab plus zimberelimab and etrumadenant in first-line PD-L1&#x2265;50% metastatic NSCLC. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus and Gilead are pursuing a broad development program for domvanalimab-based combinations in NSCLC, with three ongoing or soon-to-be initiated registrational Phase 3 trials:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.2410416666666666;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">STAR-121, evaluating the combination of domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab with chemotherapy in first-line NSCLC PD-L1 all-comers, is expected to achieve first site initiation in the third quarter and is being operationalized by Gilead. </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-10 is evaluating domvanalimab plus zimberelimab vs. zimberelimab alone vs. chemotherapy in first-line PD-L1&#x2265;50% locally advanced or metastatic NSCLC. </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">PACIFIC-8, operationalized by AstraZeneca, is evaluating domvanalimab plus durvalumab, an anti-PD-L1 antibody, in unresectable Stage III NSCLC.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">The companies are also advancing the study of domvanalimab plus zimberelimab-based combinations with two new studies in GI cancers, which are on track to start by year-end:</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-21, a Phase 2 trial evaluating</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">domvanalimab plus zimberelimab-based combinations in upper GI cancers, is open for enrollment and is intended to support the registrational Phase 3 trial STAR-221.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">STAR-221, a randomized Phase 3 study, will evaluate a domvanalimab plus zimberelimab-based combination in upper GI cancers.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Upcoming Anti-TIGIT Milestones:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Topline disclosure from the Phase 2 ARC-7 study is expected in the second half of 2022 with a planned presentation of the data at a medical conference in 2023. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus and Gilead expect to initiate two Phase 2 platform lung studies evaluating novel domvanalimab-based combinations, including domvanalimab plus zimberelimab-based triplet combinations with etrumadenant, Trodelvy&#174; (sacituzumab govitecan-hziy), and/or quemliclustat, by year-end.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Etrumadenant (A2a/A2b adenosine receptor antagonist)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Upcoming Etrumadenant Milestones:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Topline disclosure from the Phase 2 ARC-7 study is expected in the second half of 2022 with a planned presentation of the data at a medical conference in 2023.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Data from the randomized cohort of ARC-6 evaluating etrumadenant plus zimberelimab and docetaxel versus docetaxel in second-line metastatic castrate-resistant prostate cancer (CRPC) are anticipated in-house in the second half of 2022</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">with a presentation of results expected in 2023. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Data from ARC-9, a Phase 1b/2 study evaluating etrumadenant-based combinations in second-line and third-line metastatic colorectal cancer (mCRC), are expected in the first half of 2023.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Quemliclustat (small-molecule CD73 inhibitor)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Update on ARC-8:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">The ARC-8 study includes two stages: the first stage is a dose-escalation and dose-expansion stage evaluating quemliclustat plus a chemotherapy doublet and zimberelimab (the quad) followed by the second stage, a randomized cohort comparing the quad versus quemliclustat plus a chemotherapy doublet in first-line PDAC. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus conducted an interim analysis for ARC-8, which included patients from the first stage of the trial and the initial two-thirds of patients from the second stage. </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">At this interim analysis, we continued to observe encouraging data from patients treated in the first stage of ARC-8. However, data from patients treated in the randomized portion were similar to historical benchmarks for chemotherapy alone.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">At the time of data cut off, no unexpected safety signals were observed.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">The companies plan to wait for more mature PFS and overall survival data from all 90 patients in the randomized cohort to inform next steps for the PDAC program. These data are expected in the first half of 2023.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Upcoming Quemliclustat Milestones:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">As mentioned above, Arcus and Gilead expect to initiate a Phase 2 platform study to evaluate domvanalimab and quemliclustat combinations in NSCLC by year-end. We also expect to explore quemliclustat-based combinations in GI cancers in the ARC-21 study.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">AB521 (HIF-2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Arial;min-width:fit-content;">a</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> inhibitor)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">AB521 Update:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus is on track to initiate ARC-20, a Phase 1/1b study to explore the safety and clinical activity of AB521 in cancer patients in Q3 2022. Data from the ongoing healthy volunteer study enable Arcus to start dose escalation in patients at a pharmacologically relevant dose level. Pharmacokinetic (PK)/pharmacodynamic (PD) data for AB521 in healthy volunteers demonstrate its potential to have an improved clinical profile compared to the approved HIF-2a inhibitor. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Discovery Programs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">AB598 (anti-CD39 antibody) continues to progress through preclinical development, and we expect to file an Investigational New Drug (IND) application and initiate a Phase 1 trial in cancer patients in the first half of 2023. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus nominated a new small molecule development candidate, AB801, a potent and selective AXL inhibitor, which has the potential to address various treatment-resistant tumor types, such as STK11-mutant NSCLC.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus expects to nominate a potential first-in-class small molecule candidate designed to treat a wide range of inflammatory conditions in the second half of 2022.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">As part of Arcus&#x2019;s and Gilead&#x2019;s research collaboration, the companies have now selected targets for the two drug discovery programs in oncology. Upon completion of certain IND-enabling activities, Gilead has the right to exercise its option for a payment of $60 million for each program.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Financial Results for the Second Quarter 2022</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Cash, cash equivalents and investments: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">were $1,271.1 million</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">as of June 30, 2022, compared to $681.3 million as of December 31, 2021. The increase was primarily due to the receipt of $725 million from Gilead in January 2022. Arcus expects cash, cash equivalents and marketable securities on-hand to be sufficient to fund operations into 2026.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Revenues: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Collaboration and license revenues were $26.8 million for the three months ended June 30, 2022, compared to $9.5 million for the same period in 2021. In the three months ended June 30, 2022, Arcus recognized $16.7 million in license and development service revenues for all programs optioned by Gilead, based on estimates of progress made toward satisfying the related performance obligations, $8.3 million in collaboration revenue related to Gilead&#x2019;s ongoing rights to access Arcus&#x2019;s research and development pipeline in accordance with the Gilead collaboration agreement, as well as $1.8 million related to the collaboration agreement with Taiho. In the three months ended June 30, 2021, Arcus recognized $7.7 million in other collaboration revenue related to Gilead's access to Arcus&#x2019;s research and development pipeline, as well as $1.8 million related to the Taiho collaboration agreement. Collaboration and license revenues were $44.8 million for the six months ended June 30, 2022, compared to $18.9 million for the same period in 2021.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">R&amp;D Expenses:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> Research and development expenses were $69.9 million for the three months ended June 30, 2022, compared to $68.8 million for the same period in 2021. Arcus&#x2019;s expanding clinical and development activities for domvanalimab and zimberelimab drove increases in manufacturing and clinical costs. Arcus&#x2019;s growing employee base and 2022 stock awards drove an increase in employee compensation costs, including a $0.7 million increase in non-cash stock-based compensation to approximately $7.7 million. The above increases in research and development costs were mostly offset by increased cost-sharing reimbursements compared to the same quarter in the prior year. The increase in cost-sharing reimbursements was driven by the four programs optioned by Gilead in the current quarter, compared to a single program in the same quarter of the prior year. Research and development expenses were $131.1 million for the six months ended June 30, 2022, compared to $135.2 million for the same period in 2021.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">G&amp;A Expenses:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> General and administrative expenses were $25.8 million for the three months ended June 30, 2022, compared to $16.8 million for the same period in 2021. The increase was driven by the increased administrative costs to support the growing size and complexity of Arcus's clinical </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">development organization associated with Arcus's expanding clinical pipeline and collaboration obligations. Arcus's growing employee base and 2022 stock awards drove increases in employee compensation costs and facilities expense, including a $1.6 million increase in non-cash stock-based compensation to approximately $8.0 million for the three months ended June 30, 2022 compared to the prior year period. General and administrative expenses were $49.8 million for the six months ended June 30, 2022, compared to $32.6 million for the same period in 2021.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Net Loss:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> Net loss was $66.6 million for the three months ended June 30, 2022, compared to a net loss of $76.0 million for the same period in the prior year. Net loss was $134.6 million for the six months ended June 30, 2022, compared to a net loss of $148.6 million for the same period in the prior year.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Arcus Ongoing and Announced Clinical Studies</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.083%;"></td>
    <td style="width:26.462%;"></td>
    <td style="width:27.33%;"></td>
    <td style="width:20.724%;"></td>
    <td style="width:14.401%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Trial Name</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arms</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Setting</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Status</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT No.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Lung Cancer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">zim vs. dom + zim vs. etruma + dom + zim</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">1L NSCLC (PD-L1 &#x2265; 50%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing Randomized Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT04262856</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">PACIFIC-8</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">(AZ)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">dom + durva vs. durva</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Curative-Intent Stage 3 NSCLC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing Registrational Phase 3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT05211895</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-10</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;dom + zim vs. zim vs. chemo</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">1L NSCLC (PD-L1 &#x2265; 50%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing Registrational Phase 3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT04736173</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">STAR-121</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">(GILD)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;dom + zim + chemo vs pembro + chemo</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">1L NSCLC (PD-L1 all-comers)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Planned Registrational Phase 3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">TBD</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">EDGE-Lung</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">dom + zim +/- quemli</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">1L/2L NSCLC (lung cancer platform study)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">In Planning Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">TBD</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Lung Platform (GILD)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">dom + zim +/- etruma or sacituzumab govitecan (Trodelvy) or other combos</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">1L/2L NSCLC (lung cancer platform study)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">In Planning Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">TBD</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Gastrointestinal Cancers</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-9</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">etruma + zim + mFOLFOX vs. SOC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">2L/3L/3L+ CRC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Randomized Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT04660812</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-21</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">dom + zim &plusmn; chemo</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">1L/2L Upper GI Malignancies</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT05329766</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">STAR-221</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">dom + zim + chemo vs. nivo + chemo</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">GI Malignancies</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Planned Registrational Phase 3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">TBD</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Pancreatic Cancer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">1L, 2L PDAC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing Randomized Phase 1/1b</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT04104672</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Prostate Cancer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">etruma + zim + SOC vs. SOC (Adding sacituzumab govitecan (Trodelvy) combination cohorts)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">2L/3L CRPC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing Randomized Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT04381832</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Various</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">AB308 + zim</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Advanced Malignancies</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Phase 1/1b</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT04772989</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-14</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">AB521</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Healthy Volunteers</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ongoing</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">NCT05117554</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">ARC-20</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">AB521</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Cancer Patients / ccRCC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Planned Phase 1/1b</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1243750000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">TBD</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;min-width:fit-content;">dom: domvanalimab; durva: durvalumab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; quemli: quemliclustat; SOC: standard of care; zim: zimberelimab; ccRCC: clear-cell renal cell carcinoma</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;min-width:fit-content;">CRC: colorectal cancer; CRPC: castrate-resistant prostate cancer; GI: gastrointestinal; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.231458333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">About the Gilead Collaboration</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">In May 2020, Gilead and Arcus entered into a 10-year collaboration that provided Gilead immediate rights to zimberelimab and the right to opt into all other Arcus programs arising during the collaboration term. In November 2021, Gilead and Arcus amended the collaboration in connection with Gilead&#x2019;s option exercise for three of Arcus&#x2019;s then-clinical stage programs. For all other programs that are in clinical development or new programs that enter clinical development thereafter, the opt-in payments are $150 million per program. Gilead&#x2019;s option, on a program-by-program basis, expires after a specified period of time following the achievement of a development milestone for such program and Arcus&#x2019;s delivery to Gilead of the requisite qualifying data package. Concurrent with the May 2020 collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus. That stock purchase agreement was amended and restated in February 2021 in connection with Gilead&#x2019;s increased equity stake in Arcus from 13% to 19.5%, with an additional $220 million investment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Gilead and Arcus are co-developing and equally share global development costs for five clinical candidates, including domvanalimab, an Fc-silent anti-TIGIT antibody, etrumadenant, a dual adenosine A2a/A2b receptor antagonist, quemliclustat, a small molecule inhibitor of CD73, and zimberelimab, an anti-PD1 antibody.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">About Arcus Biosciences</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences&#x2019; clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Forward-Looking Statements</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein, including, but not limited to, the statements in Dr. Rosen&#x2019;s quote, Arcus&#x2019;s expectation that its cash, cash equivalents and marketable securities on-hand are sufficient to fund operations into 2026, future data disclosures and presentations, the projected achievement of clinical study milestones and their associated timing (including under the captions &#x201c;Upcoming Anti-TIGIT Milestones,&#x201d; &#x201c;Upcoming Etrumadenant Milestones,&#x201d; &#x201c;Upcoming Quemliclustat Milestones,&#x201d; &#x201c;AB521 Update,&#x201d; and &#x201c;Discovery Programs&#x201d;), and additional clinical studies in planning or expected to be initiated this year are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus&#x2019;s actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks associated with preliminary and interim data not being guarantees that future data will be similar; the unexpected emergence of adverse events or other undesirable side effects; difficulties or delays in initiating or conducting clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials, all of which may be exacerbated by the COVID-19 pandemic; Arcus&#x2019;s dependence on the collaboration with Gilead for the successful development and commercialization of its optioned molecules; difficulties associated with the management of the collaboration activities or expanded clinical programs; changes in the competitive landscape for Arcus&#x2019;s programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed on August 3, 2022 with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Investor Inquiries:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"><br>Pia Banerjee	<br>Head of Investor Relations &amp; Strategy<br>(617) 459-2006<br>pbanerjee@arcusbio.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Media Inquiries:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"><br>Holli Kolkey<br>VP of Corporate Communications<br>(650) 922-1269<br>hkolkey@arcusbio.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">ARCUS BIOSCIENCES, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> (In thousands, except share and per share amounts)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.882%;"></td>
    <td style="width:1.24%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.818999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.24%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.597000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.24%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.779%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.24%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.96%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">June 30,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">June 30,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Revenues:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">License and development service revenue</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">16,693</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">24,632</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Other collaboration revenue</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">10,066</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">9,461</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">20,132</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">18,922</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Total revenues</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">26,759</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">9,461</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">44,764</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">18,922</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Research and development</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">69,905</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">68,771</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">131,116</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">135,158</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">25,836</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">16,826</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">49,810</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">32,647</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">95,741</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">85,597</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">180,926</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">167,805</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(68,982</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(76,136</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(136,162</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(148,883</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Non-operating income (expense):</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Interest and other income, net</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">2,861</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">166</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">3,443</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">320</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Effective interest on liability for sale of future royalties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(511</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(902</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Total non-operating income, net</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">2,350</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">166</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">2,541</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">320</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Net loss before income taxes</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(66,632</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(75,970</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(133,621</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(148,563</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(1,004</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Net loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(66,632</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(75,970</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(134,625</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(148,563</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(2,584</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(44</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(5,983</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(90</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(69,216</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(76,014</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(140,608</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(148,653</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(0.93</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(1.09</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(1.88</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">(2.17</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average number of shares used to<br>&#160;&#160;&#160;compute basic and diluted net loss per share</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">71,814,232</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">69,745,297</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">71,506,216</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">68,421,086</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Selected Consolidated Balance Sheet Data</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> (In thousands)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.667%;"></td>
    <td style="width:1.734%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.932%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.734%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.932%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">June 30,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;min-width:fit-content;">(1)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and investments in marketable securities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,271,105</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">681,298</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,476,773</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,591,898</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">729,387</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">750,448</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">747,386</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">841,450</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">(1) Derived from the audited financial statements for the year ended December 31, 2021, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 23, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img230044022_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img230044022_0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Z!#L# 2(  A$! Q$!_\0
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MKR#FCFCFCFO:,0YHYHYHYH _17_@E)\5MT7BSX<W<W*D:UIZL>QVQ3J/_()
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M%O,+<VV<#./XTR<!UXY .#Q7KE?,5*<J<G":LT="=]4%%%%9C"BBB@ HHHH
M**** "HKJZAL;>6XN)HX+>)2\DLK!510,DDG@ 5\^_M)?MK^!OV>XIM.:7_A
M)/%^W]WHEC*/W3=C<2<B(>V"QX^7'-?F'\=/VKOB'^T!>2+XAU=K71=VZ+0]
M/)BLTYR-RYS(P_O.2?3'2O7PF65L5[S]V/?_ ",I5%$_1?XR_P#!1OX8?#-Y
MK'0I9?'6L1DJ8])<+:*P[-<$%2/>,/7Q?\3/^"D/Q=\=/+#I%Y:>#-.8_+%I
M,(:?;Z--)N;/N@6OE?FCFOJZ&5X:A]GF?G_5CFE4E(V/$WC+7_&E\UYX@UO4
M=<NV))FU&Z>=^?=R:Q^:.:.:]5))61F'-'-7M+T'4]<D,>FZ==ZA(.JVL#2G
M\E!KI8_@K\0IH]\?@/Q-(F,[ET>X(_\ 0*ESC'=@<9S1S6_JWP]\4Z#&7U/P
MUK&G(O):[L)8@/\ OI16!S5*2ELP.\^'WQX^(?PKE1O"OC#5M(C3I;1W!>W/
MUA?*'\5KZ]^$/_!536=/D@LOB1X=AU:UX5M4T4"&X4?WFA8['/\ NE/I7P-S
M1S7)6P=#$+]Y'Y]2HS<=C]Y?A-\=O WQOTK[=X.\0VNJE%#36F3'<P?]=(FP
MRC)QG&#V)KOZ_GL\/>)-5\(ZQ;:MHFHW6DZG;-OAN[.5HI8SZAE.:^T? _\
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MRJG_ '5%>W45\E7S#$XA^]*R[+0ZE",>A7L=/M=+MUM[.VAM+=?NQ01A%'T
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MO3AS:LT_#_A_3?">B66CZ-8P:;I=E$(;>TMD"1Q(.@ %:-%%?":O5G8%%%%
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MG460D$6L0WR#(Z%@ @/8N*_<BSLX-/M(+6UACMK:!%BBAA4*D:*,*J@<
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M'IN!\QNGWU!'R"OK&FHBQJJ(H55& JC  IU?F5>M+$5)59;L]&*Y59!1116
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M4 %%%% !1110 4444 %?D5_P4V_Y.>G_ .P1:?\ L]?KK7Y%?\%-O^3GI_\
ML$6G_L]>]DO^]?)_H8UOA/E#FCFCFCFONCB.A^'?_)0/#/\ V%+7_P!'+7]
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MV,H3'DR(JCYWVDJ=S+PB>E1?#G_@EY\,_"YCG\4:AJGC*Z4@M&[_ &.V./\
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M/_HIZ_;:OQ)_8H_Y.F^'7_80/_HIZ_;:OE\\_CQ]/U9T4?A"BBBOG#<****
M/ OVN_V5],_:6\$A(##I_C'3%9]*U)Q\ISRT$N.3&WKR5.&&?F5OQR\9^"]<
M^'GB:^\/^(],GTC6+&3RY[6X7#*>Q!Z,I&"&!(((()!K^@JO(?VAOV8/!G[1
M^A):^(;9K75[9"MCK5H +FVZG:3_ !QY/*-QR2,'FO=R_,GA?W=36'Y&-2GS
M:K<_#GFCFO<?V@?V/?B!^SW=S3ZI8'6/#>[$6OZ<A>WP>@D'6)O9N,]"U>'<
MU]M3J0K1YZ;NCC::T8<T<T<T<UJ(.:.:.:.: -GPOXSU_P #ZBM_X>UO4-#O
M5((GTZZ>!^/4J1D5](_#K_@I+\7_  5Y4.JW=AXPLEX*:M;A9MOM+%M.?=@U
M?*O-'-<]7#TJW\2*92DX['ZF?#O_ (*G?#[7_*@\7:%JGA2Y8#?/ !>VP/<Y
M4"3\ AKZ@\ ?&[P#\4H5?PIXMTG6G//V>WN5$Z_[T38=?Q6OP3YIT,SV\J21
M.T<B'<KH<$$="#7C5LEH3UIMQ_%?U\S95GU/Z(J*_$OX:?MJ?&#X6M%'I_B^
MZU2PC&!8:W_ID6WT!?YU'^ZPK[&^$?\ P50\,ZTT5G\0O#]QX<N#\IU+2\W-
MJ?=H_P#6(/8;Z\.OE&)I:Q7,O+_(U56+/NZBN;\"_$;PO\3-'75/"NO6&O6)
MQF6QG5]A/9QU0^S &NDKQ7%Q=FM38****0!1110 4444 %%%% !1110 4444
M %%%% !1110!\Z_M[?%?_A5?[..O_9YO*U77\:+:8/S#S0?-;U&(EDP>S%:_
M&7FOLS_@J!\5_P#A+OC-I_@ZTFWV'A>TQ,JG@W<X5WZ=<1B$>QWBOC/FOO\
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M[J*X26&$JZ,CA@RX7J".*VCQO.I[KRZJK_X?\T92R>G%76)@_O/J>BBBLCS
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M"_[!OP.\*LKQ>!X-2F4Y\S5+F:YS]4=]G_CM>T^&_"&A>#K,6F@Z+I^B6O\
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M:^L/*&R1K-&R-G:P*G!P:_9?]CF[\-_%WX!^%O$,]DEYK$, T[4FGD+G[1
MC,1]T;U"R8QP)!UK\:N:^\_^"5/Q6_LOQAXF^'UY-B#58!JEBK'@3Q8655'J
MT95OI#7S6?9=0QV'4ZU-2=/572=K[VO\ON.W#8BK0DU3DXWWL['Z26>C6&G
M"ULK>VQT\F)5_D*NT45\3"$::Y8*R.B4I2=Y.X44459(4444 %%%% !7Y%?\
M%-O^3GI_^P1:?^SU^NM?D5_P4V_Y.>G_ .P1:?\ L]>]DO\ O7R?Z&-;X3Y0
MYHYHYHYK[HXCH?AW_P E \,_]A2U_P#1RU_0'7\_GP[_ .2@>&?^PI:_^CEK
M^@.OD,]^*G\_T.JCLPHHHKY8Z3Y9_;J_91C^/G@K_A(- ME_X3S1(3]EV@ W
M]N"6:V8_WN2R9Z,2. Y(_(.:&2WF>*5&CE1BK(XPRD<$$=C7]$5?F]_P4<_9
M+_LVYNOBUX2LO]&N'W>(;*%?]7(>!=J!V8\28_B(?G<Y'U&48[D:PU1Z/;_(
MYZL/M(_/SFCFCFCFOL#D.J^&'Q,U_P"#_CC3/%?AJ[^R:I82;EW9,<J'AHI%
MS\R,,@CWX(."/VR^ 7QST#]H+X=V7BC0W\IV_=7VGNX:2RN  6B;U'.5; W*
M0<#H/PCYKV#]F#]HW6/V;?B-%K=F)+O1;O;!J^EAL"Z@!ZC/ D3)*M[D=&;/
MC9E@5BX<T/C6WGY&U.?*]=C]Q**P_!7C/1_B'X5TOQ)X?O8]1T?4H5GMKB/H
MRGJ".H8'*E3R""#R*W*^!:<79G:%%%%( HHHH **** /!OVZ-%_M[]E+X@0!
M=S0VL5V/;RKB.0G\D-?BIS7[]_%+PO\ \)Q\,_%GAW;O.JZ5=62K_M21,H_4
MBOP%96C9E92K*<$$8(K[+(IWI3AV?Y_\,<E;=,3FCFCFCFOICG+6EZA)I.J6
M=]#_ *ZUF29/]Y6!'ZBOZ#])U*'6=*LM0MSNM[N%)XSZJRAA^AK^>;FOV^_8
MY\;#Q[^S/X U(R>9-#IRZ?,>^^W)@.?<^6#^.:^7SVG>$*G9M??_ ,,=-%ZM
M'LU%%%?'G4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &'XY_Y$GQ!_V#[C_T6U?S[\U_01XY_P"1)\0?]@^X_P#1;5_/OS7UV0_#
M4^7ZG+6Z!S1S1S1S7U1S'V=_P2I_Y+_X@_[%N;_TIMJ_5:ORI_X)4_\ )P'B
M#_L6Y_\ TIMJ_5:O@LX_WI^B.VE\(4445XAL%%%% !1110 4444 %%%% !11
M10!^/7_!2+_DZK7_ /KQLO\ T0M?,'-?3_\ P4B8-^U9KX!SBRL@?^_"U\P<
MU^EX+_=J?HOR."?Q,]N_8H_Y.F^'7_80/_HIZ_;:OQ)_8H_Y.F^'7_80/_HI
MZ_;:OE\\_CQ]/U9T4?A"BBBOG#<***Y7Q;\5/!G@.-V\2>*]&T/;U6_OHH6_
M!6;)/T%5&+D[15P.JHKSCX:_M#_#SXQ:YJ>D>#O$MOKM]IL2SW*012*H1F*@
MJS* XR.=I.,CUKT>G*$J;Y9JS%>^P4445 PHHHH **** *>J:18ZY8R6>I65
MOJ%G(,/;W42RQM]58$&O OB)^P+\%_B%YDO_  C'_"-WCY_TGP_*;7&?^F>#
M%_XY7T316U.M4HN].30FD]S\U_B+_P $H-9LQ+/X'\96NHIC*V6MPF"3Z>;'
MN#'ZJHKY5^)W[,'Q0^$/FR^)O!VH6UC'UU"V07-KCU,L995_X$0?:OW2I&4,
M"",@U[-'.<13TG:2^XR=*+V/YW.:.:_:OXO?L2_"?XQ+//>^'8]#UB7)_M70
MP+6;=CJR@;'/3EE)XZU\#_'C_@G+\0?A;'<ZIX8/_"=:!'ER;&(I>PJ,GYH,
MG?@=XRQ[[17T.'S7#XCW6^5^?^9A*G*)\F<T<TZ2-H9&1U9'4[65A@@CJ"*;
MS7L&(<UI>&_$FJ>#]?L-;T6^FTW5;&99[:Z@;#QN#P1_@>""0:S>:.:32:LQ
MG[<?LF_M&67[2'PO@U@B*V\1V!6UUFQC/$<V,B11U$<@!9?3#+DE2:]LK\6/
MV(_CA)\$/CMH]Q<W/D^'M:9=+U56;"".1@$F/8>6^UL]=N\#[U?M/7Y[F6$^
MJUK1^%ZK_([:<N9!1117E&H4444 %%%% !1110 4444 %?B_^WA\6/\ A:W[
M1WB%[>;S=*T,C1;/!XQ"3YK#L<RF4@]QMK]5/VDOBHGP7^"/BSQ8)%2\M+0Q
MV(/.;J0B.'CN [*3[*:_"F21II&=V9W8[F9CDDGJ2:^IR.A=RKOIHOU.:M+H
M-YHYHYKM?@K\.;CXN?%CPMX0MPW_ !-KZ.&5TZQP@[IG'^[&KM_P&OK924(N
M4MD<V^A^J_\ P3W^%7_"M?V<-'N[F'R]4\2.VLS[ASY;@" 9]/*5&QV+M7TQ
M4%C90:;96]G:Q+;VMO&L4448PJ(H 50/0 "IZ_+ZU5UJDJCZL]%*RL%%-9EC
M5F9@JJ,EB< "OA?]JK_@HYIW@MKSPO\ "V2WUC7$)BG\0,!+9VIZ$0CI,X_O
M?<'^WR!>'P]7$SY*:N*4E%79]*?'C]I;P/\ L\Z+]K\3ZENU&5"UIH]IA[NY
M_P!U,_*N?XV(7C&<\5^6W[1G[;/CS]H&:YT]K@^&_"+,0FAZ?(<2KV\^3@RG
MVP%_V<\UX9XD\2ZMXQUR[UG7-1N=5U6[?S)[N[D,DDC>Y/Z#L!BLWFOML'EE
M+"VE+WI=_P#(Y)5'(.:3W[5H^'/#>K>,-<M]'T'3;C5]5G_U=K:KN;'=F/1%
M'=F( K[!^#_[%^D^'_(U7QZ\/B'5!ATTB$DV$!ZXD/!G8>^$XZ&O.S[B;+>'
M:?-C)^^]H+63^71>;LOGH=^ RS$YC/EH1TZM[+^NQ\V_"WX%>,/C!*LNB6 M
MM'W;9-:U#,=HOKL.,RGV0'ZBOL/X6?LH^"OANT%[>0?\)7KT?S"^U.,&*)O6
M*#E5^K;F]Z^@/"O@W4/$TL=KIEJL=M"!'O"A((%[#@8 Q_"!^%>W^$/A?I7A
M94G=?M^H#G[1*O"G_87M]>M?AV)SSB'C%N&'?U?#/LWJO.6CEZ+ECW1]K'"9
M9D:O6_>U>W;Y;+YW?8\P\+_"?6/$GESW>=.LR!AYA\[#_93T^N!7KGAGX>Z+
MX757MK8370ZW,_SOGV[+^%=-17M97PW@,K2E"/-/^9ZOY=%\M?,\/&YQBL;[
MLI<L>R_7N%?A?^U%\,?^%/\ QZ\8^&HXO)L8;UKBQ4#C[-*!+$!Z[5<*?=37
M[H5^='_!5[X8[+CP=\0;:+APVB7K@=QNE@/U(,XS_LK7Z/D];V>(Y'M+\SYZ
MJKQN?GES1S1S1S7W1Q!S79_!GXC7/PD^*GA?Q?:[BVDWT<\B(<&2'.V6/_@4
M;.O_  *N,YHYJ914HN+V8]C^AO3M0MM6T^VOK.9;BTN8EFAFC.5=& *L/8@@
M_C5FOF#_ ()V_%;_ (61^SIIFG7,WF:IX8E.D3!C\QA4!K=L>GEL$'_7,U]/
MU^85Z3H594WT9Z,7=7"BBBL!A1110 4444 %?D5_P4V_Y.>G_P"P1:?^SU^N
MM?D5_P %-O\ DYZ?_L$6G_L]>]DO^]?)_H8UOA/E#FCFCFCFONCB.A^'?_)0
M/#/_ &%+7_T<M?T!U_/Y\._^2@>&?^PI:_\ HY:_H#KY#/?BI_/]#JH[,***
M*^6.D*KWUC;:G97%G>01W5I<1M#-!,@=)$8$,K*>"""00?6K%% 'XS_MJ?LL
MW'[.?C[[1ID4DW@C67:33+@Y;[.W5K5V/\2]5)^\N#DD-CYSYK]\OB[\*M!^
M-/P_U7PEXB@\VPOH\+*@'F6\H^Y-&3T=3R.QY!R"0?Q%^-'PAUWX&?$35/"/
MB"+%U:-NAN$4B.Z@;/ES1^JL!^!#*>017WF68[ZS#V<W[Z_%=_\ ,XJD.5W1
MP_-'-'-'->X8GU7^PO\ M<2_ ?Q8/#7B2Z9O 6KS#S68D_V;.< 3J/[AX#CT
M 8<KAOUUM[B*Z@CFAD6:&10Z21L&5E(R"".H(K^=_FOT*_X)V_M@?96L/A+X
MSO?W3MY7A[4;AONL>EF['L3_ *O/<[.Z ?+YME_.GB*2UZK]3IIS^RS]&J**
M*^/.H**** "BBB@ K\,/VJ/ )^&?[0GCK01'Y5O'J4ES;+C@038FC ]<+(!^
M!K]SZ_-K_@JU\*VL]>\)_$.UA_<7D1T>^=1@"5-TD)/J64RCZ1"O>R:M[/$<
MC^TOQ,:JO&Y\ <T<T<T<U]T<0<U^E/\ P2C^):WOA;Q?X#N)?W]A<+JUHC'D
MQ2 1R@>RLD9^LM?FMS7K_P"R;\8O^%'_ !W\-^([B4Q:0\OV'4^>/LLN%=CZ
M[#MDQZQBO/Q]#ZQAY06^Z^1I"7+*Y^XM%-5ED565@RL,A@<@BG5^;G>%%%%
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M0*?%KX0Q>&-3N0_B;PJB6D@=OGGL\8@E'K@#RVZ\HI)^<5]85^#?P)^,VL?
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M+7] =?S]?#^01>/?#;M]U=3MB?PE6OZ!:^1S[XJ?S_0ZZ/4****^5.@****
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M444 %%%% !1110 45!>7EOI]K-=7<\=M;0J7DFF<(B*.26)X 'J:^)?VDO\
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M?5G>%%%% !7Y2?\ !4KPG_8_Q\TG6D7$6L:+$S-CK+%(\;?^.>57ZMU\$_\
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M:B_9UTK]I'X:W&A71CM-;M2UQI&I,.;:?&,,1SY;X"L.>QQE5K\4?%?A75?
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M[17XO:+^WU\==#C")XYDNT QMO;&VF/_ 'TT>[]:UYO^"CGQUD3:OB:RB/\
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M@AXJ_P# ^'_XQ1_PZU^#_P#T$/%7_@?#_P#&*/[9POG]P>RD?D[S1S7ZQ?\
M#K7X/_\ 00\5?^!\/_QBC_AUK\'_ /H(>*O_  /A_P#C%']LX7S^X/92/R=Y
MHYK]8O\ AUK\'_\ H(>*O_ ^'_XQ1_PZU^#_ /T$/%7_ ('P_P#QBC^V<+Y_
M<'LI'Y.\T<U^L7_#K7X/_P#00\5?^!\/_P 8H_X=:_!__H(>*O\ P/A_^,4?
MVSA?/[@]E(_)WFOWU^#W_)(_!'_8#L?_ $G2OFS_ (=:_!\_\Q'Q5_X'P?\
MQBOJ_P -Z#;>%_#NEZ+9M(UIIUK%9PM,VYRD:!%+'N< 9->'FF.I8N,%2OH;
M4X.-[GXB_M8?\G+?$O\ [#UU_P"C#7E'-?L!X\_X)T_"[XB>--;\4:I?^)$U
M'5[N2\N%M[V)8Q([;F"@PD@9/ )-8/\ PZU^#_\ T$/%7_@?#_\ &*]>EF^&
MA3C%WT2Z&3I2N?D[S1S7ZQ?\.M?@_P#]!#Q5_P"!\/\ \8H_X=:_!_\ Z"'B
MK_P/A_\ C%:_VSA?/[A>RD?D[S1S7ZQ?\.M?@_\ ]!#Q5_X'P_\ QBC_ (=:
M_!__ *"'BK_P/A_^,4?VSA?/[@]E(_)WFCFOUB_X=:_!_P#Z"'BK_P #X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"&V?@G_P!#Y:_^ ES_ /&J /<**\T^'W[2'PW^*GB Z)X5\40:OJGDM/\
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M*** "BBB@ HHK!\;^.-#^''AF[\0>)-032]'M2@FNI$9@F]PB\*">68#@=Z
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M *635\+_ /!0[_DYK5_^O"S_ /10K[H_87_Y-7\#_P"Y=_\ I9-3 ]YHHHI
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MT^\U:WMKBVN$#I+&[A64@^H)K:_:8^!>H?L\_%2ZTA3,VD3M]LT>_)P9("W
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M^A^T_P#[]S?_ !% 'M%%<SX ^)'AGXI:(^L>%=7AUK38YVMFN( P D4*2IW
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M]V.-,_4L?_9:[^&Z?M<VH1\[_<F_T./.9^SP%5^5OO:1[)1117]('XX%%%%
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M_10K[H_87_Y-7\#_ .Y=_P#I9-7PO_P4._Y.:U?_ *\+/_T4*^Z/V%_^35_
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M.^#KSX>_"OPIX9U"6">^TG38;.:2V),;.B $J2 2..X%=C10 4444@"BBB@
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MA[2*._\ $HW#^(+[_P#L?_MV6NCZ;9>"/B5>F*WMU6'3O$,N6"H.%BN#U '
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M_P#);/A__P!C#I__ *4QU^T/C[_D1/$?_8-N?_135^+OP-_Y+7\/O^QAT_\
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M,?\ P3S&@WUGXF^**6]W<Q$2V_AN-A)$C#D&X8?*^/\ GFN5]2PRM?=( 48
MP*6BI **** "BBB@#\GO^"AW/[36K\?\N%G_ .BA7W/^PO\ \FK^!^WR7?\
MZ635[K):PR-N>*-V]64$T](UC4*BA%'0*,"F ZBBBD 4444 8'C[_D1?$?\
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,%4 "KU( HHHI ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rcus-20220803.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-03T16:13:12.3581+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://arcusbio.com/20220803" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:rcus="http://arcusbio.com/20220803" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20220803_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20220803_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>rcus-20220803_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-03T16:13:12.3979+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>rcus-20220803_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-03T16:13:12.3950+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rcus-20220803.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140483629490720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  03,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcus Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001724521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3898435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3928 Point Eden Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-6200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCUS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>rcus-20220803_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rcus-20220803.xsd" xlink:type="simple"/>
    <context id="C_d6315451-4815-46e3-900e-dd17359d1acd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2022-08-03</startDate>
            <endDate>2022-08-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_4bf4238c-f038-47b6-ba94-d5e703e07bb5">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_61b2860c-73c8-45b6-92d3-697c4fa9fb07">0001724521</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_c8fa1abe-e71b-4da8-a560-493133adfda7">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_d4e66e4b-568e-4472-b647-434afa82800e">2022-08-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_d9106a3a-17b0-450f-ae35-98c33f906cb6">Arcus Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_77f6fdde-1a7c-4a40-bb95-8f769f12e71d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_2144b5eb-9a91-4602-9521-3d3076cc33b9">001-38419</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_7f9a192b-52dd-478c-9173-e29a97d8699e">47-3898435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_4e663137-3172-4170-95fe-39e68276e817">3928 Point Eden Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_1e3ce3c9-99a1-44ad-92e0-afe13d76c1dc">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_d99bce71-8e50-4b5c-b5c4-3d60094733d6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_40160431-678d-4ffe-aff9-d247a2a21c15">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_47756395-8107-4e55-babc-78774be22302">(510)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_04a6de1a-bd49-46d4-834f-4a56b4f14709">694-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_47f69b45-d621-49c0-b672-c608b604c32c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_d50c704b-b9f9-4eff-ac87-e55dd397abfa">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_a13a321c-0288-4dc0-bcef-7ea02074235c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_3a116d8d-c101-4265-aeaa-e0ee3ba3bd1e">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_69e04cd3-96c5-46cf-a875-0080f379398e">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_8fa77cd2-3524-4bfa-b877-288b8548f0fe">RCUS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_843034bb-2173-4263-9855-2f1020726d24">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_d6315451-4815-46e3-900e-dd17359d1acd"
      id="F_dfea854f-8583-4302-834d-98eb653defad">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR<."%$EB@Z3?@R0.^GZ[@Q%6CN^BAGTDG$01V#5LK\,!^0+WD6]I?>YPR?;
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ $8(#5660>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( !&" U6L,WI7[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !&" U697)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ $8(#58;C,AA9!   FA   !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !&" U6?H!OPL0(
M .(,   -              "  9P,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rcus-20220803.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="rcus-20220803.htm">rcus-20220803.htm</File>
    <File>rcus-20220803.xsd</File>
    <File>rcus-20220803_lab.xml</File>
    <File>rcus-20220803_pre.xml</File>
    <File>rcus-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rcus-20220803.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "rcus-20220803.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rcus-20220803_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rcus-20220803_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rcus-20220803.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rcus",
   "nsuri": "http://arcusbio.com/20220803",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rcus-20220803.htm",
      "contextRef": "C_d6315451-4815-46e3-900e-dd17359d1acd",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "rcus-20220803.htm",
      "contextRef": "C_d6315451-4815-46e3-900e-dd17359d1acd",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://arcusbio.com/20220803/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-22-014263-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-014263-xbrl.zip
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MP,)N\J%,4(UE[1W)$&41 %1]]:>H_-'L%5_(O/LPIHEVI(1S]]5N)B/:5U5
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M9Z3#2>=6C<P,F9G],S-?0 TCF*W1$YE(@'UM/NHU!V.6N4V)DQ1P&MT$XZ7
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M8:$5N7CDXKU\7_W[8B_D0;:&LK#(,A*>F"0*Z^H)'ZH0 GYJL">)W%S0L2"
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M:_CM%29NR3HLIRD6Y^0VFJL,S!-,U-*4W&;W88NU-*<==/FMZUXLO0M/I*
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M22J[)&TB^*#]TFR0N_+LE_:1QTFD)/P9)Q+KG6;OM)6[05(43$;P59;J] A
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MY([4_)TTZT#[9A_D<3^(78">%KO"6)9=7U]7.0X'K*S"&Z/PF-B:P2/@B9?
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M5KV^BL)_248B8IX:PX-&(HSEE7A&79?:S[;O&%'[F97N$;6?[8Z35'=:7>K
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M_C]02P$"% ,4    "  1@@-52T8)6JD3  "\YP  $0              @ $
M    <F-U<RTR,#(R,#@P,RYH=&U02P$"% ,4    "  1@@-5S'B6W@X#  "8
M"0  $0              @ '8$P  <F-U<RTR,#(R,#@P,RYX<V102P$"% ,4
M    "  1@@-5[ J279<%  #],0  %0              @ $5%P  <F-U<RTR
M,#(R,#@P,U]L86(N>&UL4$L! A0#%     @ $8(#50 A,(V#!   Y"0  !4
M             ( !WQP  ')C=7,M,C R,C X,#-?<')E+GAM;%!+ 0(4 Q0
M   ( !&" U6IEQ3$438  !^8!  /              "  94A  !R8W5S+65X
>.3E?,2YH=&U02P4&      4 !0!! 0  $U@

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
